BRIEF-Celgene Corp and bluebird bio announce bb2121 anti-BCMA CAR-T cell therapy has been granted Breakthrough Therapy designation from FDA
November 16, 2017 at 08:42 AM EST
* Celgene Corp and bluebird bio announce bb2121 anti-BCMA CAR-T cell therapy has been granted Breakthrough Therapy designation from FDA and prime eligibility from EMA for relapsed and refractory multiple myeloma
